Acumen Pharmaceuticals (ABOS) 10-Q2024 Q1 Quarterly report

Filed: 14 May 24, 4:47pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: acquired, acquiring, Agency, agree, allocated, alternative, annum, arm, attributable, banking, began, bifurcated, borrowed, borrowing, building, called, Carlo, Charlottesville, commencement, compound, conclusion, country, coupon, curtail, damage, deployment, derivative, discount, dividing, dollar, elevated, EMA, embedded, enhance, equivalent, escalation, essentially, European, expression, extensive, facility, fairly, faster, fee, feedback, final, foreign, frequency, fundraising, gene, glutamine, host, immaterial, implement, implemented, imposition, incidence, injury, institutional, instrument, Israel, lease, leased, leasing, leave, lending, liability, lowest, meaningful, Monte, neuronal, Newton, October, patient, PD, pharmacodynamic, prudent, pursuit, quantitative, recognition, recommence, reconciliation, Redemption, registered, remeasured, returned, sabirnetug, Scale, slightly, space, staffing, standalone, structure, synaptic, synthetase, tightening, toxin, unfavorable, unobservable, vendor, Virginia

Removed: absence, acted, administered, application, ARIA, arterial, ASC, blood, bound, broader, calculating, capability, cerebral, closed, Codification, codified, computerized, conflict, consistency, defending, detection, enforcing, entity, evidenced, exploratory, extend, FASB, favorable, flow, forfeited, guidance, immunogenicity, inclusive, inform, inherent, initially, intravenously, issuable, joint, labelling, laboratory, line, located, magnetic, manager, mechanism, methodology, MRI, objective, participating, partnership, percent, plasma, prefer, preliminary, preparing, presence, pricing, promulgated, proof, prosecuting, reacquired, reclassification, reclassified, replace, repurchased, requisite, resonance, restrictive, satisfy, service, settled, spin, submitted, Suisse, supportable, Topic, trade, typically, UBS, updated, USA, valuable, vesting, voting, withheld, withholding

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ABOS transcripts

ABOS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION OF PERIODIC FINANCIAL REPORTS PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Acumen Pharmaceuticals, Inc. (the “Company”) for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Matthew Zuga, Chief Financial Officer and Chief Business Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1.The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 14, 2024	By:	/s/ Matthew Zuga
		Matthew Zuga
		Chief Financial Officer and Chief Business Officer (Principal Financial Officer and Principal Accounting Officer)